Trastuzumab, CAS 180288-69-1

Product Description: Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer[1][2][3]. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70./[2]Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51./[3]Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72.

CAS Number: 180288-69-1

Molecular Weight: (145.36 kDa)

Compound Purity: 99.80

Research Area: Cancer

Solubility: H2O

Target: ADC Antibody;EGFR;Radionuclide-Drug Conjugates (RDCs)

• SKU: MEXHY-P9907-25
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P9907-25
• Package Unit: 25 mg
• Quantity Unit: STK
• Conjugate: Unconjugated